Panaji Journal

PCSK9 Inhibitors Market Size was approximately USD 1,309 million in 2021

 Breaking News
  • No posts were found

PCSK9 Inhibitors Market Size was approximately USD 1,309 million in 2021

January 13
18:13 2023
PCSK9 Inhibitors Market Size was approximately USD 1,309 million in 2021

The PCSK9i Market report provides emerging drugs, PCSK9i market share of the individual cancer types, current and forecasted PCSK9i market size from 2019 to 2032 segmented by seven major markets. The Report also covers current PCSK9i unmet medical needs to curate best of the opportunities and assesses underlying potential of the market

 

The PCSK9 Inhibitors market dynamics are anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world and rising cases of statin resistance in patients with Familial Hypercholesterolemia as well as increasing risk of cardiovascular conditions such as myocardial infarction, coronary revascularization etc. Key players, such as LIB Therapeutics, Ionis Pharmaceuticals, AstraZeneca, CiVi Biopharma, and others are currently developing PCSK9 Inhibitors drugs.

 

Key takeaways from the PCSK9 Inhibitor Market Report

  • In 2021, the total PCSK9 Inhibitors market size was approximately USD 1,309 million which is expected to rise during the study period (2019–2032).
  • In 2021, the total PCSK9 Inhibitors market size was approximately USD 1,309 million which is expected to rise during the study period (2019–2032).
  • In the year 2021, the total prevalent cases of Familial Hypercholestrolemia was 3,129.5 K cases in the 7MM which are expected to grow during the study period, i.e., 2019–2032.
  • The leading PCSK9 Inhibitor Market Companies include AstraZeneca, Ionis Pharmaceuticals, CiVi Biopharma, LIB Therapeutics, Merck Sharp & Dohme, Sanofi, Regeneron Pharmaceuticals, Amgen, Novartis, Alnylam Pharmaceuticals, and others.
  • Promising PCSK9 Inhibitor Pipeline Therapies include LIB003, AZD8233 (ION449), Cepadacursen sodium (CIVI-007), CiVi-008, and others.

 

Explore more information on the latest breakthroughs in the PCSK9 Inhibitors Treatment Landscape @ PCSK9 Inhibitors Market Size

 

PCSK9 Inhibitors Overview

Proprotein convertase subtilisin/Kexin type 9 serine protease (PCSK9) plays a vital role in cholesterol metabolism by regulating low-density lipoprotein (LDL) receptor degradation, which reduces the clearance of circulating LDL particles. PCSK9 activity is inversely related to LDL cholesterol (LDL-C) level: Gain-of-function PCSK9 gene mutations are one cause of elevated LDL-C and cardiovascular risk in familial hypercholesterolemia (FH), whereas loss-of-function mutations cause low LDL-C and reduced risk of atherosclerotic cardiovascular disease (ASCVD).

 

PCSK9 Inhibitors Epidemiology Segmentation in the 7MM

  • Total PCSK9 Inhibitors Prevalent Cases
  • Total PCSK9 Inhibitors Diagnosed Cases
  • PCSK9 Inhibitors Type-specific Cases
  • PCSK9 Inhibitors Age group-specific Cases
  • PCSK9 Inhibitors Mutation-specific Cases
  • PCSK9 Inhibitors Risk factor-specific Cases of PCSK9 Inhibitors in Prophylactic/Preventive setting
  • Total PCSK9 Inhibitors Treated Cases

 

Find new updates of the PCSK9 Inhibitors Market Trends of the report @ PCSK9 Inhibitors Market Forecast

 

PCSK9 Inhibitors Market Insights

Monoclonal antibodies directed at PCSK9 are the first to be approved. There are currently two FDA approved PCSK9 inhibitors namely, alirocumab and evolocumab available in the United States for adult patients to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease as an adjunct to diet, alone or in combination with other lipid-lowering therapies, for the treatment of adults with primary hyperlipidemia (including HeFH) to reduce LDL-cholesterol.

 

PCSK9 Inhibitors Key Players and Therapies

  • LIB003 (Lerodalcibep): LIB Therapeutics
  • AZD8233 (ION449): AstraZeneca and Ionis Pharmaceuticals
  • Cepadacursen sodium (CIVI-007): CiVi Biopharma
  • CiVI-008: CiVi Biopharma

 

Get to know more about the PCSK9 Inhibitors Recent News, Updates of the market report @ PCSK9 Inhibitors Ongoing Clinical Trials Analysis

 

PCSK9 Inhibitors Market Dynamics

The dynamics of the PCSK9 Inhibitors market is expected to change in the coming years due to several factors such as the improvement in the rise in the number of healthcare spending globally and rising cases of statin resistance in patients with familial hypercholesterolemic as well increasing risk of cardiovascular conditions such as myocardial infarction, coronary revascularization etc. Furthermore, the PCSK9 inhibition in a prophylactic setting can relieve the CVD burden and thus impacting the PCSK9 Inhibitors market positively. In addition, the implications of PCSK9 inhibitors in broader therapy areas also contribute towards the growth of the PCSK9 Inhibitors market. Though monoclonal antibodies have, for the time being, established themselves as the most clinically useful inhibitors of PCSK9, other novel therapies are currently in various stages of development and will be available soon in the PCSK9 Inhibitors market.

 

Scope of the PCSK9 Inhibitors Market Report

  • Coverage- 7MM
  • PCSK9 Inhibitors Companies- AstraZeneca, Ionis Pharmaceuticals, CiVi Biopharma, LIB Therapeutics, Merck Sharp & Dohme, Sanofi, Regeneron Pharmaceuticals, Amgen, Novartis, Alnylam Pharmaceuticals, and others
  • PCSK9 Inhibitors Pipeline Therapies- LIB003, AZD8233 (ION449), Cepadacursen sodium (CIVI-007), CiVi-008, and others.
  • PCSK9 Inhibitors Market Dynamics: PCSK9 Inhibitors Market Drivers and Barriers

 

Table of Content

1. Key Insights

2. Report Introduction

3. Table of Contents

4. PCSK9 Inhibitors Market Overview at a Glance

5. Executive Summary of PCSK9 Inhibitors (PCSK9i)

5.1. Key Events

6. Epidemiology and Market Methodology

7. PCSK9 Inhibitors (PCSK9i) Background and Overview

8. Guidelines

9. Epidemiology and Patient Population

10. Patient Journey

11. Key Endpoints in PCSK9 inhibitor Clinical Trials

12. Marketed drugs

13. Emerging Therapies

14. Attribute Analysis of PCSK9 Inhibitors

15. PCSK9 inhibitors: 7 Major Market Analysis

16. Market Access and Reimbursement

17. KOL Views

18. SWOT analysis

19. Unmet Needs

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Discover more information on the PCSK9 inhibitors Market Dynamics @ PCSK9 inhibitors Market Drivers and Barriers

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles